Back
Top 0.3%
22.8%
Top 46%
15.0%
Top 0.9%
9.2%
Top 0.5%
6.6%
Top 43%
6.1%
Top 20%
5.7%
Top 1.0%
4.3%
Top 1%
4.0%
Top 2%
2.0%
Top 20%
2.0%
Top 3%
2.0%
Top 0.8%
1.6%
Top 2%
1.6%
Top 23%
1.0%
Top 0.4%
1.0%
Top 62%
1.0%
Top 8%
0.7%
Top 7%
0.7%
Differentiating Borderline HER2-Expressing and HER2-Positive Cancers from Other Subtypes Using Serum Urokinase Plasminogen Activator
2026-01-16
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundHER2-positive (HER2+) cancers are associated with aggressive tumor development but also high response rates to targeted blockade treatments of the HER-2/neu signaling pathway leading to improved clinical outcome for the patient. Current clinical analysis of the HER2 status primarily relies on solid tumor biopsies low-suitable for continuous real-time monitoring needed for possible adjustment of the treatment, while serum tests targeting blood-circulating HER-2/neu fragments often show ...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
Frontiers in Oncology
34 training papers
4
Clinical Cancer Research
22 training papers
5
Scientific Reports
701 training papers
6
Nature Communications
483 training papers
7
British Journal of Cancer
22 training papers
8
Cancer Medicine
17 training papers
9
BMC Cancer
21 training papers
10
eLife
262 training papers
11
iScience
74 training papers
12
Communications Biology
36 training papers
13
Diagnostics
36 training papers
14
JAMA Network Open
125 training papers
15
Archives of Clinical and Biomedical Research
18 training papers
16
BMJ Open
553 training papers
17
PeerJ
46 training papers
18
International Journal of Molecular Sciences
39 training papers